Further detail from G306 Phase III field trial | 07-May-2024 | 07:00 | RNS |
Director Resignation | 03-Apr-2024 | 07:00 | RNS |
Interim Results for six months ended 31 Dec 2023 | 27-Mar-2024 | 07:00 | RNS |
Update on funding | 27-Mar-2024 | 07:00 | RNS |
VLP Peanut PROTECT Trial Update | 12-Mar-2024 | 08:59 | RNS |
Appointment of Shaun Furlong to Board of Directors | 11-Mar-2024 | 07:00 | RNS |
Result of AGM | 08-Mar-2024 | 13:49 | RNS |
Half-Year Trading Update 2024 | 14-Feb-2024 | 07:00 | RNS |
Notice of 2023 Annual General Meeting | 09-Feb-2024 | 15:07 | RNS |
Restoration - Allergy Therapeutics plc | 30-Jan-2024 | 07:30 | RNS |
Publication of Annual Report and Accounts 2023 | 30-Jan-2024 | 07:00 | RNS |
Total Voting Rights | 04-Jan-2024 | 12:29 | RNS |
Suspension - Allergy Therapeutics plc | 02-Jan-2024 | 07:30 | RNS |
Amendment to existing Facility Agreement | 27-Dec-2023 | 12:01 | RNS |
Annual Report and Accounts Delayed | 15-Dec-2023 | 12:48 | RNS |
Currency | UK Pounds |
Share Price | 3.30p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 6.25 |
52 Week Low | 0.88 |
Volume | 0 |
Shares Issued | 4,766.44m |
Market Cap | £157.29m |
RiskGrade | 268 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
No dividends found |
You are here: research